Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Perioperative Management in Inherited Thrombocytopenia
NCT03638817Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Aug 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in inherited thrombocytopenia, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Perioperative management by eltrombopag in inherited thrombocytopenia at 4 weeks. Started Aug 2019; status: completed.
02
Drugs
eltrombopag
03
Conditions
inherited thrombocytopenia
Beyond the preview
Go deeper on NCT03638817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638817.